JP7438975B2 - Cxcr3リガンド - Google Patents
Cxcr3リガンド Download PDFInfo
- Publication number
- JP7438975B2 JP7438975B2 JP2020559959A JP2020559959A JP7438975B2 JP 7438975 B2 JP7438975 B2 JP 7438975B2 JP 2020559959 A JP2020559959 A JP 2020559959A JP 2020559959 A JP2020559959 A JP 2020559959A JP 7438975 B2 JP7438975 B2 JP 7438975B2
- Authority
- JP
- Japan
- Prior art keywords
- cxcr3
- cxcr3 ligand
- g1t4k
- g1t4h
- vhn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018227353 | 2018-12-04 | ||
| JP2018227353 | 2018-12-04 | ||
| PCT/JP2019/047382 WO2020116498A1 (ja) | 2018-12-04 | 2019-12-04 | Cxcr3リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020116498A1 JPWO2020116498A1 (ja) | 2021-10-14 |
| JPWO2020116498A5 JPWO2020116498A5 (cg-RX-API-DMAC7.html) | 2022-12-07 |
| JP7438975B2 true JP7438975B2 (ja) | 2024-02-27 |
Family
ID=70974705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559959A Active JP7438975B2 (ja) | 2018-12-04 | 2019-12-04 | Cxcr3リガンド |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US12624077B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3892330A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7438975B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020116498A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3892330A4 (en) | 2018-12-04 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | CXCR3 LIGAND |
| CA3194929A1 (en) * | 2020-06-21 | 2021-12-30 | Technion Research & Development Foundation Limited | Modified cxcl10 for immunotherapy of cancer diseases |
| US20230242606A1 (en) * | 2020-06-21 | 2023-08-03 | Technion Research & Development Foundation Limited | Cxcl9 and variants thereof for immunotherapy of cancer diseases |
| WO2023120643A1 (ja) | 2021-12-23 | 2023-06-29 | 中外製薬株式会社 | Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。 |
| CN121338000B (zh) * | 2025-11-13 | 2026-08-04 | 中山大学 | Rab30-dt抑制剂在制备预防和治疗肿瘤的药物中的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003082335A1 (fr) | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe |
| JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999028474A2 (en) | 1997-12-01 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services | Chemokine variants and methods of use |
| AU2903999A (en) * | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US7091310B2 (en) * | 2002-09-13 | 2006-08-15 | Chemokine Therapeutics Corporation | Chemokine analogs for the treatment of human disease |
| US20090131312A1 (en) | 2005-05-18 | 2009-05-21 | Lawrence Blatt | Non-natural chemokine receptor ligands and methods of use thereof |
| US7696309B2 (en) | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
| EP3096777B1 (en) | 2014-01-21 | 2021-01-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Goblet cell replacement therapy |
| EP3892330A4 (en) | 2018-12-04 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | CXCR3 LIGAND |
| WO2021038033A1 (en) | 2019-08-29 | 2021-03-04 | Antagonis Biotherapeutics Gmbh | T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity |
| WO2023120643A1 (ja) | 2021-12-23 | 2023-06-29 | 中外製薬株式会社 | Cxcr3発現細胞遊走活性が増強したcxcr3リガンド。 |
-
2019
- 2019-12-04 EP EP19893138.8A patent/EP3892330A4/en active Pending
- 2019-12-04 US US17/299,629 patent/US12624077B2/en active Active
- 2019-12-04 JP JP2020559959A patent/JP7438975B2/ja active Active
- 2019-12-04 WO PCT/JP2019/047382 patent/WO2020116498A1/ja not_active Ceased
-
2026
- 2026-04-08 US US19/641,701 patent/US20260217779A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003082335A1 (fr) | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe |
| JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3892330A4 (en) | 2022-10-26 |
| US12624077B2 (en) | 2026-05-12 |
| US20260217779A1 (en) | 2026-07-30 |
| US20220017585A1 (en) | 2022-01-20 |
| WO2020116498A1 (ja) | 2020-06-11 |
| JPWO2020116498A1 (ja) | 2021-10-14 |
| EP3892330A1 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12006361B2 (en) | Albumin binding domain fusion proteins | |
| US12624077B2 (en) | CXCR3 ligand | |
| CN113474367A (zh) | 结合cd3和hla-a*02限制性肽的半衰期延长的immtac | |
| CN108602871A (zh) | 用于治疗自身免疫疾病的选择性地活化调节性t细胞的分子 | |
| CN105518025A (zh) | 人抗IFN-α抗体 | |
| US20240376172A1 (en) | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues | |
| JP5581214B2 (ja) | 改善された結合活性をもつ可溶性gp130変異蛋白質 | |
| US20250073307A1 (en) | Cxcr3 ligand having enhanced cxcr3-expressing cell migration activity | |
| US20020052475A1 (en) | High affinity soluble interleukin-18 receptor | |
| CN121194988A (zh) | 白细胞介素-2变体及其应用 | |
| AU2019305086B2 (en) | Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity | |
| HK40108361A (en) | Cxcr3 ligand having enhanced cxcr3-expressing cell migration activity | |
| RU2854870C2 (ru) | Агонисты il-15 для лечения рака | |
| EP4719458A2 (en) | Il10 inverted monomers | |
| EP4562059A1 (en) | Il-15 agonists for cancer | |
| HK40126456A (en) | Albumin binding domain fusion proteins | |
| HK40015886B (en) | Albumin binding domain fusion proteins | |
| HK40015886A (en) | Albumin binding domain fusion proteins | |
| EP3325515B1 (en) | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240129 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7438975 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |